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Abstract
Survivin (BIRC5), a member of the inhibitor of apoptosis protein (IAP) family that inhibits caspases and blocks cell
death is highly expressed in cancer and is associated with a poorer clinical outcome. Functioning simultaneously
during cell division and apoptosis inhibition, survivin plays a pivotal role in determining cell survival. Survivin has
consistently been identified by molecular profiling analysis to be associated with higher tumor grade, more
advanced disease, abbreviated survival, accelerated rates of recurrence, and chemotherapy and radiation resistance.
Survivin’s differential expression in cancer compared to normal tissue and its role as a nodal protein in a number
of cellular pathways make it a highly flexible therapeutic target, suitable for small-molecule inhibitiors, molecular
antagonists, and vaccination-based therapies. By targeting survivin it is hoped that multiple tumor signaling
circuitries may be simultaneously disabled. This effect may be applicable to many tumor histologies irrespective of
specific genetic makeup. To date, survivin inhibitors have shown modest activity as single agents, but it is
anticipated that when given in combination with cytotoxic chemotherapy or monoclonal antibodies they may
exhibit enhanced efficacy. This review discusses the complex circuitry of survivin in human cancers and highlights
clinical trials involving novel agents that target this important protein.
Introduction
Survivin (BIRC5), is a member of the family of inhibitors
of apoptosis proteins (IAPs) [1,2] of which eight mem-
bers are known, including X-linked inhibitor of apopto-
sis (XIAP), cIAP1,c I A P 2, NAIP (NLR family, apoptosis
inhibitory protein), livin, ILP2 (IAP-like protein 2),
BRUCE and survivin [3,4]. Survivin, the smallest family
member, is a 142-amino acid, 16.5 kDa protein encoded
by a single gene located on the human 17q25 chromo-
some, consisting of three introns, and four exons [2,5,6]
and exists physiologically as a functional homodimer
[7,8]. Alternative splicing of survivin pre-mRNA pro-
duces five different mRNAs with the potential to encode
up to five distinct proteins, survivin, survivin 2B, survi-
vin ΔEx3, survivin 3B and survivin 2a[9-11]. Survivin
has been implicated in both control of cell survival and
regulation of mitosis in cancer [5,12-14]. Survivin is pre-
ferentially and highly expressed in cancer cells, with lit-
tle expression in most normal non-dividing adult tissues
(Table 1) [5]. The integral role of survivin in cancer cell
division and survival makes it an attractive therapeutic
target to inhibit cancer cell growth [1,2]. It was origin-
ally suggested that survivin inhibits cell death induced
via the extrinsic and intrinsic apoptotic pathways and
confers resistance to apoptosis by directly suppressing
caspase activity [14]. Although the exact mechanism of
action is unknown, current evidence is that most IAPs,
including survivin, block apoptosis by mechanisms other
than by direct initiator or effector caspase inhibition
[15-17]. Survivin is now thought to function upstream
of the effector caspases by inhibiting caspase 9 [18], by
forming a survivin-hepatitis B X-interacting protein
(HBXIP) complex bound to pro-caspase-9 thereby pre-
venting the recruitment of apoptotic protease activating
factor 1 (Apaf-1) to the apoptosome [19]. Additionally
survivin associates with XIAP enhancing its inhibition of
caspase-9 activation [20]. Survivin is inhibited by
SMAC/DIABLO (second mitochondria-derived activator
of caspases/direct inhibitor of apoptosis binding protein
with low pI) which results in the displacement of bound
IAPs, which, may then bind to and inhibit caspase func-
tion [21,22].
Some investigators have suggested that the primary
function of survivin is in controlling cell division, rather
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lated during cell division and is closely associated with
centrosomes and mitotic spindle microtubules. It con-
trols chromosome spindle-checkpoint assembly, thereby
ensuring normal cell division. Survivin is maximally
expressed during the G2M phase of the cell cycle and
exists predominantly as a multi-protein complex, known
as the chromosomal passenger complex (CPC) [25-27].
By functioning in this complex survivin can facilitate
accurate sister chromatid segregation and stabilization
of the microtubules in late mitosis [23]. In addition to
its direct role in carcinogenesis, survivin may also play a
key role in tumor angiogenesis as it is strongly
expressed in endothelial cells during the proliferative
phase of angiogenesis [12,28,29]. Manipulating the survi-
vin pathway may facilitate endothelial cell apoptosis and
promote vascular regression during tumor angiogenesis
[29]. Increased expression of survivin also appears to be
associated with an increasedr i s ko ft u m o rp r o g r e s s i o n
and chemoresistance in many tumor types [30-41].
Results of in vitro and in vivo studies have shown that
survivin down-modulation reduces tumor-growth and
sensitizes tumor cells to chemotherapeutic agents such
as taxanes, platinum agents, etoposide, gamma-irradia-
tion, and immunotherapy [42]. As an example, resis-
tance to docetaxel is associated with increased levels of
survivin [43], and response is often associated with the
degree of expression of the various survivin splice var-
iants [44].
Mechanism of Action of Survivin
Cellular apoptosis is controlled by two pathways. The
extrinsic pathway is critical for immune selection and
inflammation. It is initiated by the activation of cell
death receptors, such as tumor necrosis factor alpha
(TNF-a) receptor, located at the cell membrane. The
intrinsic pathway is initiated by toxic insult such as
radiation or chemotherapy (DNA damaging and anti-
microtubule agents) [45]. The two pathways converge at
caspase-3 and follow a common process of activating
caspases that cause cell death by cleaving essential sub-
strates for cell survival, such as cytoskeletal proteins,
DNA repair proteins, and inhibitory subunits of endonu-
cleases [46]. Upon activation of the intrinsic pathway,
mitochondrial permeability is increased resulting in the
release of both cytochrome C and SMAC/DIABLO.
Cytochrome C activates the apoptosome, which in turn
activates caspase-mediated proteolysis involved in cell
death [47].
S M A C / D I A B L Oa c t sa sa ni n h i b i t o ro ft h eI A P s .
Upon activation of pro-apoptotic cell signaling, survivin
is released from the mitochondria and inhibits caspases-
3 and -9. This function requires association with hepati-
tis B X-interacting protein (HBXIP) and/or with X-
linked IAP (XIAP) and is inhibited by SMAC-DIABLO
[47]. The regulation of survivin expression and function
is complex and occurs at various levels, including tran-
scription, differential splicing, protein degradation, and
intracellular sequestration via different ligands [47]. Sur-
vivin expression is up-regulated at a transcriptional level
by both nuclear factor-appa b (NF-B) which in turn,
can be activated indirectly by growth factors via the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway and
by TCF-4/b-catenin pathway [48-50]. The insulin like
growth factor-1/mTOR/RAS and Wnt-2 signaling path-
ways have also been reported to up-regulate survivin via
rapid changes in mRNA translation [51-53]. Survivin
degradation occurs via the ubiquitin-proteasome path-
way in the G1 phase of the cell cycle and is stabilized
when bound to heat shock protein 90 (Hsp90) [54]. The
survivin protein is closely associated with Cdc2/Cdk1
a n di ti sp h o s p h o r y l a t e da tt h et h r e o n i n e - 3 4( T 34)r e s i -
due. This phosphorylation stabilizes the protein and
allows it to interact with the mitotic spindle and inhibit
caspase-9 [55].
There is accumulating evidence that molecular cha-
perones play a key role in the regulation of survivin.
Binding of survivin to the immunophilin aryl hydrocar-
bon receptor-interacting protein (AIP) [56] or to heat
shock protein-90 (Hsp90) [54] maintains its stability
against proteasome dependent destruction. Heat shock
protein-60 (Hsp60) has also been identified as a molecu-
lar chaperone for survivin [57]. Acute ablation of Hsp60
by small interfering RNA (siRNA) has been shown to
destabilize the mitochondrial pool of survivin leading to
enhanced mitochondrial dysfunction and caspase-depen-
dent apoptosis. This response involves disruption of the
Hsp60-p53 complex, which results in p53 stabilization,
increased expression of pro-apoptotic Bax, and subse-
quent Bax-dependent apoptosis [57].
Table 1 Over-expression of survivin in common human
malignancies
Cancer Expression (%)
Lung cancer 85.5% [76]
Esophageal cancer 80% [128]
Breast cancer 70.7% - 90.2% [33,129]
Pancreatic cancer 76.9% - 88% [130,131]
Ovarian cancer 73.5% [132]
Malignant melanoma 67% [67]
Colorectal cancer 63.5% [40]
Hepatocellular cancer 41%-87% [133,134]
Gastric cancer 34.5% - 68% [37,135]
Bladder cancer 57.8% [136]
Acute myeloid leukemia 54.8% [137]
Acute lymphocytic leukemia 68.8% [137]
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Survivin plays a central role in cell division, where its
expression is coordinated within the cell cycle [2,47].
Survivin levels increase in G1 and peak in the G2M
phase. During mitosis, survivin functions as a regulator
of microtubule dynamics and as part of the chromoso-
mal passenger complex (CPC). Survivin functions both
at the centrosomes and the microtubules of the meta-
phase and anaphase spindle providing stabilization and
ensuring accurate separation of sister chromatids
[2,58,59]. Survivin also localizes to the kinetochores,
the mid-region or centromeric portion of the meta-
phase chromosomes. Here survivin is associated with
regulators of cytokinesis, such as Aurora B kinase, the
inner centromere protein antigens (INCENP), and Bor-
ealin/Dasra [60,61]. This supports the hypothesis that
survivin acts as a subunit of the CPC which is required
for proper chromosome segregation and cytokinesis
[62]. It follows that if survivin is removed from the
system, the kinetochore-microtubule system is not
properly formed, cell divisioni se i t h e rh a l t e do ri m p r o -
perly completed, and ultimately cell death occurs. Sur-
vivin is also bound to microtubules located in the
mitotic apparatus during cell division. Through its
association with cyclin-dependent kinase 1 (CDK1),
microtubule-bound survivin becomes phosphorylated
on Thr34 [1]. This leads to stabilization of the protein
and efficient counter-activation of apoptosis in dividing
cells. Elimination of survivin leads to apoptosis of
dividing cells.
Survivin Expression in Cancer Cells
Survivin is undetectable in most non-proliferating adult
tissues. Exceptions are CD34+ hematopoietic stem cells,
placenta, basal cells of the colonic epithelium, and thymus
[5]. On the other hand, survivin is over-expressed in a
wide variety of cancers (see Table 1) [5]. Overexpression is
correlated with advanced disease, accelerated time to
recurrence, reduced survival, and resistance to therapy
[38]. Survivin has been identified as one of 16 genes within
an mRNA expression signature that, in patients with
breast cancer, correlates with a poor response to tamoxi-
fen, but a good response to chemotherapy [63]. Further-
more, inhibition of in vitro or in vivo survivin expression
by antisense oligonucleotides, or inhibition of survivin
function by in vitro inhibition of CDK1-mediated phos-
phorylation leads to cell death [58]. This is particularly
apparent when CDK1 inhibition is combined with taxanes
[58]. Recently the mTOR pathway, which can act as a sen-
sor network in stressed conditions, has been implicated in
elevating survivin levels [51]. In prostate cancer cells, insu-
lin-like growth factor-1 (IGF-1)-mediated mTOR pathway
activation positively modulated survivin levels by increas-
ing the translation of a survivin mRNA pool [51].
The role of survivin in malignant melanoma
Genes that are highly expressed in aggressive melanomas
includes many with roles in cell cycle regulation/prolif-
eration, DNA replication/repair, and apoptosis pathway-
related genes. Survivin is variably expressed in the
cytoplasm across the spectrum of melanocytic lesions,
with nuclear expression detectable in a subset of malig-
nant melanomas, but not in benign or dysplastic nevi
[64]. Nuclear expression has been reported to be an inde-
pendent predictor for disease recurrence and decreased
overall survival in patients with early stage cutaneous
melanoma [65]. Patients with nuclear immunoreactivity
for survivin showed an increased risk of melanoma recur-
rence during the first three post-operative years and an
increased risk of death. Cytoplasmic survivin staining has
not demonstrated a correlation with patient survival [65].
This suggests that the nuclear localization of survivin
m a yp l a yar o l ei nt h et r a n s f o r m a t i o np r o c e s s .C h e na n d
co-workers demonstrated the up-regulation of survivin in
primary melanomas as compared to benign nevi [66].
Similarly, Nasr et al found immune-histochemistry (IHC)
nuclear staining for survivin was present in 12 of 18 cases
(67%) of malignant melanoma with an average index of
7% (range 0%-15%), and no nuclear staining was present
in any benign lesions examined [67]. Expression of survi-
vin, bcl-2, bax, and bcl-X in sentinel lymph node (SLN)
biopsies was assessed in 36 patients with stage I and II
melanoma using RT-PCR and Southern blotting and cor-
related to overall survival. Survivin expression correlated
with the outcome of patients in a statistically significant
way (P < 0.005), whereas the expression of bcl-2, bax,
a n db c l - X ,d i dn o ts e e mt oc o rrelate to progression of
disease [68]. In this study, 61.5% of patients expressing
survivin in the SLN progressed or died of melanoma. In
patients negative for survivin expression, 100% were dis-
ease-free at a median follow-up time of 52.9 months sug-
g e s t i n gt h a ts u r v i v i ng e n ee x p r e s s i o ni nS L N sm a yb ea
useful prognostic indicator. There was no correlation
between bcl-2, bax,a n dbcl-X gene expression and out-
come [68]. Survivin expression has been studied in a lim-
ited number of non-cutaneous melanomas. In uveal
melanomas, expression of survivin was reported to be
low and did not correlate with outcome, resistance of the
tumor to brachytherapy, or the presence of liver metas-
tases [69]. Survivin expression has also been reported in
a case of esophageal melanoma [70], but its impact is
unclear. A phase II study investigated YM155 (section
5.1), a small molecule survivin suppressor as a single
agent first line treatment in 34 patients with metastatic
melanoma. One patient had a complete response, one
had a partial response, and 11 had stable disease
97.
The role of survivin in solid tumors
Survivin expression has been detected in a wide variety
of benign and pre-neoplastic lesions including polyps
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hypertrophic actinic keratosis [71]. Survivin has been
shown to play an important role in colorectal tumori-
genesis by stimulating the transition of adenomas with
mild dysplasia into highly dysplastic lesions [72]. This
transition was associated with a significant decrease in
the apoptotic index (AI) and significant increases in
the Ki-67 labeling index (LI) and microvessel density
(MVD) (P < 0.001). The expression of survivin inver-
sely correlated with AI and was positively correlated
with Ki-67 LI and MVD (P < 0.001). In esophageal
cancer, survivin expression has been correlated with a
poor prognosis whereby the median survival for
patients with high levels of survivin expression was
reduced compared to patients with low expression
levels [73]. In this study the median survival for
patients with advanced esophageal cancer and with
high levels of survivin expression was 9.0 months com-
pared to 30.0 months for those patients with low survi-
vin expression (p = 0.0023) suggesting that survivin
expression may provide prognostic information. Simi-
larly patients with advanced gastric cancer with survi-
vin-positive tumors have a significantly lower 5-year
survival rate compared to patients with survivin-nega-
tive tumors (P < 0.05) [74]. In non-small cell lung
cancer (NSCLC), survivin is over-expressed in approxi-
mately 80% of tumors and its presence is associated
with a reduced survival in patients with resected neo-
plasms [75,76].
Expression of survivin also correlates with resistance
to therapy. In prostate cancer cells treated with doce-
taxel, apoptosis is induced by the binding of survivin to
SMAC/DIABLO and to the mitotic spindle [77]. Naka-
hara et al have reported that YM155 (Section 5.1)
induced regression of established hormone refractory
prostate cancer (HRPC) xenografts [78]. In vitro,d o c e -
taxel resistance was reversed in gastric cancer cells
when messenger ribonucleic acid (mRNA) expression of
survivin was down-regulated by gambogic acid, a survi-
vin inhibitor [43].
Preliminary results are available for a phase II trial
investigating 168-hour continuous iv infusion of YM155
(Section 5.1) in patients with metastatic HRPC who
have received prior taxane therapy. The primary end-
point of this trial is PSA response rate. Data on 32
patients has been reported and 2 PSA responders were
seen indicating YM155 may have some activity in HRPC
[79]. An ongoing study is investigating the combination
of YM155 and docetaxel in patients with HRPC and
preliminary data appear promising. Survivin over-
expression has been associated with platinum and tax-
ane-based chemotherapy resistance in a number of solid
tumors [80,81]. It is postulated that vascular endothelial
growth factor (VEGF) induced angiogenesis may lead to
a transient increase in survivin levels [82] suggesting a
role for combining survivin inhibitors with anti-VEGF
strategies.
The role of survivin in hematological malignancies
Survivin expression has been observed in the majority of
malignant lymphoproliferative disorders with the excep-
tion of chronic lymphocytic leukemia in which it is
expressed at levels significantly lower than that found in
normal lymphocytes [83]. Different techniques for
detecting survivin expression have been used including
immunohistochemistry (IHC), immunoblotting, and
messenger RNA (mRNA) detection; however, no studies
comparing these methods have been performed. Three
trials have utilized IHC to determine expression of sur-
vivin in diffuse large B cell lymphoma (DLBCL) and one
study used mRNA expression. The largest study
included 222 patients from four separate randomized
trials [31]; however, the interpretation of the effect of
survivin expression on outcome is complicated by the
fact that different chemotherapy regimens were used in
the different trials. Although most regimens contained
an anthracycline, usually doxorubicin, or mitoxantrone,
some regimens did not. In this report, tumors were
characterized as being positive for survivin expression if
cytoplasmic staining was demonstrated in 70-90% of
cells, and negative if less than 5% of the tumor showed
staining. Survivin expression was observed in 60% of the
patients’ tumors and was found to confer an inferior
outcome. Patients whose tumors did not show expres-
sion of survivin had a 5-year survival of 54%, whereas
only 40% of survivin-positive cases were alive at five
years (P = 0.02). The complete remission rate was lower
in the survivin-expressing group, but not significantly
different from the survivin-negative cases at 61% versus
68%, respectively (P = 0.29). This resulted in a lower
event-free survival in the survivin-positive cases, but the
difference did not achieve statistical significance (p =
0.09). The survival difference was examined in a multi-
variate analysis incorporating the International Prognos-
tic Index (IPI) and was found to be independent of the
IPI score. In two other reports that included 60 and 39
patients, respectively, the nuclear localization of survivin
was associated with an inferior outcome in one, but not
the other [84,85]. The relatively small numbers of
patients in these studies may have accounted for this
disparity. The statistical significance was lost when the
patients in the larger study were grouped according to
whether they represented a germinal center or non-
germinal center DLBCL. There was a trend towards a
worse outcome in both subgroups, but the difference
did not achieve significance.
Survivin expression has also been evaluated using an
RNAse protection assay [86]. Here the authors
reported that survivin mRNA expression was increased
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on overall survival. Survivin protein expression was not
simultaneously examined and it is possible that transla-
tional regulation could have resulted in a disparity in
the mRNA and protein expression levels. A recent
report examining the relationship between survivin
mRNA and protein levels in patients with HTLV-1-
associated adult T cell leukemia/lymphoma (ATLL)
found a strong correlation between mRNA levels and
protein expression [87].
There has been increasing interest in survivin as a
potential therapeutic target in lymphoma. Antisense oli-
gonucleotides (ASO) have been shown to inhibit survi-
vin expression in a number of DLBCL cell lines. These
ASO inhibited cell growth in vitro a n ds l o w e dt u m o r
growth in animals [88].
Clinical studies of investigational survivin inhibitors
are ongoing in a number of hematological malignancies.
There was great enthusiasm for the small molecule imi-
dazolium-based survivin transcriptional inhibitor YM155
(Section 5.1) following the phase I trial as responses
were observed in three of five patients with relapsed B
cell lymphoma, including two patients with DLBCL [89].
These results were not reproduced in the phase II trial
that included 41 patients with relapsed and refractory
DLBCL [90]. At the time of the abstract submission,
only one of the first 25 patients enrolled and evaluated
for tumor response showed an objective response.
YM155 was well tolerated with grade 3 or 4 anemia
(16%), neutropenia (8%), fatigue (8%), and deep venous
thrombosis (8%) as the onlye v e n t st h a to c c u r r e di n
more than 4% of the patients. Due to the potential for
synergism of YM155 with other agents, additional trials
are underway or planned combining YM155 with che-
motherapy or monoclonal antibodies including rituxi-
mab and alemtuzumab.
Survivin expression may have even greater prognostic
significance in patients with T cell lymphoma
[50,87,91,92]. High levels of expression have been
reported in patients with HTLV-1-associated ATLL.
Survivin levels were greater in the aggressive acute sub-
type of the disease compared with the more indolent
chronic form of ATLL. ATLL patients whose tumors
expressed high levels of survivin had an inferior out-
come, with a median survival time of 6.4 months com-
pared to 18 months in those patients with low survivin
levels [93]. These results have been reproduced in a
number of other studies and are similar to the results
seen in DLBCL. Inhibition of survivin expression in pri-
mary ATL cells using shRNA leads to decreases in
tumor cell viability.
Anaplastic large cell lymphoma (ALCL), another rela-
tively uncommon T cell neoplasm, is separated into two
prognostic groups based on the expression of the
anaplastic large cell kinase gene (ALK). The expression
of ALK is most frequently the result of a translocation
between chromosomes 2 and 5, resulting in a unique
fusion of the ALK and nucleophosmin genes, respec-
tively. ALK-positive ALCL has a superior clinical out-
come with about 80% of patients cured with current
chemotherapy. In contrast, patients with ALK-negative
ALCL demonstrate a worse prognosis with a 50% 5-year
survival. Survivin expression was examined in ALCL
patients by IHC and was found to be frequently positive
with primarily cytoplasmic localization [92]. Approxi-
mately 63% of ALK-positive ALCL tumors expressed
survivin compared with 47% of the ALK-negative ALCL.
Absence of survivin expression in both subtypes con-
ferred an improved prognosis with 100% of the ALK-
positive, survivin-negative patients alive at 5 years, and
89% of the ALK-negative, survivin-negative patients
alive at 5-years. In contrast only 34% of ALK-positive,
survivin-positive patients were alive at 5 years. For the
ALK-negative group, the 5-year overall survival was 60%
for patients with survivin-positive tumors versus 92% for
patients with survivin-negative tumors (P = .04). Survi-
vin expression remained an independent adverse prog-
nostic marker in a multivariate analysis that included
IPI score.
Current therapeutic approaches
Transcriptional repressors
YM155 (1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyra-
zin-2-ylmethyl)-4,9-ihydro-H-naphtho[2,3-d]imidazolium
bromide) (Astellas Pharma Inc) is a small-molecule sup-
pressor of survivin. YM155 interacts specifically with the
269 base pair survivin core promoter region and func-
tions in a cell cycle independent manner as a transcrip-
tional inhibitor. YM155 has demonstrated potent anti-
proliferative activity against various cancer cell lines and
preferentially induces cell death in tumor cells. Preclini-
cal data has also shown that it has the ability to serve as
a radio-sensitizing agent and to potentiate the antitumor
activity of various cytotoxic agents including carboplatin
and paclitaxel [94,95]. In preclinical experiments,
YM155 has shown promising activity in a wide variety
of human tumor xenograft models including non-small
cell lung cancer (NSCLC) [96].
YM155 has been investigated in six phase I or II clinical
trials in solid tumors and non-Hodgkins lymphoma. It has
been shown to be well tolerated with the most common
toxicities being reported as grades 1-2 in severity and con-
sisting primarily of stomatitis, pyrexia and nausea
[97-100]. In a phase I study conducted in the United
States, 41 patients received YM155 at doses ranging from
1.8 to 6.0 mg/m
2/d by a 168-hour (7 days) continuous
intravenous infusion every 3 weeks. The maximum toler-
ated dose (MTD) was determined as 4.8 mg/m
2.I na
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with advanced refractory solid tumors were treated with
escalating doses of YM155 administered by continuous i.v.
infusion for 168-hours in 21-day cycles. Of the 34 patients
enrolled, 33 (median age, 59 years) received at least 1 dose
of YM155 and the MTD was determined to be 8.0 mg/
m
2/d. The most common adverse reactions judged to be
related to YM155 were microalbuminuria, fever, injection-
site phlebitis, fatigue, and decreased hemoglobin/anemia,
serum albumin, and lymphocyte count.
As monotherapy, YM155 has shown modest antitumor
activity in a phase II trial in patients with advanced
NSCLC who had failed one or two prior chemotherapies
[98,102]. Two partial responses were observed in 37
patients (5.4%) enrolled in this study, where YM155 was
administered as a 7 day continuous infusion at 4.8 mg/m
2/
day, repeated every 3 weeks. Fourteen patients (37.8%)
achieved stable disease resulting in a disease control rate
of 43.2% (95% CI, 27.1% to 60.5%). Median PFS was 1.7
months (95% CI, 1.3 to 2.8 months). Median overall
survival was 6.6 months (95% CI, 4 to 12.2 months), with
a 1-year survival rate of 35.1%. Treatment was well toler-
ated with the majority of treatment discontinuations not
YM155 related. A phase I/II study evaluating the combina-
tion of YM155 in combination with carboplatin and pacli-
taxel has now been initiated. YM155 is also being
investigated in malignant melanoma, HER-2/neu-negative
breast cancer, and in combination with docetaxel in hor-
mone refractory prostate cancer (see Table 2).
Terameprocol (EM-1421, Erimos Pharmaceuticals) is a
semi-synthetic small molecule with antitumor activity
occurring via selective targeting of Sp1-regulated pro-
teins, including survivin and cyclin dependent kinases
(cdc2) that control cell cycle and apoptosis [103,104].
Terameprocol is in clinical development as a site-speci-
fic transcription inhibitor in solid refractory tumors and
in leukemias.
mRNA Inhibitors
LY2181308 (ISIS/Eli Lilly Pharmaceuticals), a novel
modified ASO, is a specific inhibitor of survivin. In a
Table 2 Survivin inhibitors currently in phase I/II clinical trials
Mechanism of
action
Compound Clinical
Trials
Indication
Antisense
oligonucleotides
LY2181308 Phase I AML
Phase II AML, NSCLC (+docetaxel)
and HRPC (+docetaxel)
Terameprecol (EM-1421) Phase I Leukemia
Phase II AML, NSCLC (+/- docetaxel),
HRPC (+docetaxel)
Transcriptional
Repressors
Phase I Solid tumors
YM155 Phase II NSCLC(+carboplatin/
paclitaxel), HRPC
(+docetaxel),
HER2 negative breast cancer
(+docetaxel)
Melanoma
Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor
Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion
Phase I/II Melanoma
Multipeptide vaccine: PSMA and Survivin Phase I/II Prostate cancer
Survivin peptide vaccine Phase I/II Solid tumors
Multipeptide Vaccine: telomerase and survivin Phase I Breast cancer
Immunotherapy Multipeptide vaccine: MART-1, keyhole limpet hemocyanin, recombinant MAGE-3.1,
survivin and autologous dendritic cells
Phase I/II Melanoma
Multipeptide vaccine: MART-1, gp100 and survivin antigens + GM-CSF +/- IL2 Phase I Melanoma
Stem Cell Transplant, Chemotherapy, and Biological Therapy (CMV N495 peptide, CMV
pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal
polyvalent vaccine, survivin Sur1M2 peptide vaccine)
Phase I/II Multiple Myeloma
Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA Phase I/II Breast Cancer or Malignant
Melanoma
Survivin and telomerase peptide-pulsed dendritic cells Phase I/II Renal Cell Carcinoma
AML, Acute myeloid leukemia; CMV, cytomegalovirus; GM-CSF, granulocyte-macrophage colony stimulating factor; HRPC, hormone-refractory prostate cancer;
hTERT, human telomerase reverse transcriptase; IL-2, interleukin-2; MAGE, melanoma-associated antigen NSCLC, non-small cell lung cancer; PSMA, prostate-
specific membrane antigen.
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LY2181308 showed a safety and pharmacokinetic (PK)
profile consistent with previously described ASOs. Side
effects were mild to moderate and no grade 3 or 4 toxi-
cities were described at the MTD of 750 mg [105].
Additionally, a pharmacodynamic study has been con-
ducted in 34 patients, including 22 patients with avail-
able pre- and post-treatment biopsies. IHC indicated
that survivin expression was reduced in the nucleus and
cytoplasm in 11 of 17, and 5 of 14 evaluable pairs,
respectively. Gene expression analysis indicated a reduc-
tion in survivin expression of 20-50% in 11 of 15 evalu-
able pairs. Analysis of fresh tumor from endobronchial
sampling revealed that 2 of 3 NSCLC patients had a
near-complete elimination of survivin-positive cells
accompanied by an increase in the fraction of cells with
a sub-G1 DNA content, consistent with cell death [106].
Furthermore, a human micro-dosing imaging PK study
of an ASO with LY2181308 using carbon-11 radiola-
beled LY2181308 ([
11C]LY2181308) was conducted. In
this study pharmacokinetic analysis confirmed that bio-
logically active human tumor drug concentrations of
[
11C]LY2181308 can be achieved. LY2181308 therapy
saturated normal tissue kinetics and increased tumor
uptake of [
11C]LY2181308 [107]. LY2181308 is currently
being evaluated in phase II trials for relapsed and refrac-
tory acute myeloid leukemia, prostate cancer and
NSCLC (see Table 2). Other approaches for inactivating
specific mRNAs that remain predominantly in the pre-
clinical setting involve the use of hammerhead ribo-
zymes [108,109] and small interfering RNAs [110,111].
Small molecule survivin inhibitors
Shepherdin is a small molecule inhibitor in early stage
clinical development that acts as an antagonist of the
survivin-Hsp 90 complex [112]. This molecule is a 5
amino acid peptide that antagonizes the binding
between survivin and Hsp-90 as well as acting as a
global inhibitor of Hsp90 function via competition
with ATP.
Immunotherapy
Due to its differential expression by tumors, it has been
hypothesized that cancer patients may recognize survi-
vin as a “non-self” protein and mount an immune
response against it [113]. Phase I trials using survivin-
directed autologous cytotoxic T lymphocytes acitvated
with survivin-primed dendritic cells or survivin peptides
have been performed. Treatment was well tolerated with
limited toxicity [114,115]. Wobser et al, described an
early example of survivin-based vaccination therapy in a
patient with metastatic pancreatic cancer that achieved
a complete regression of liver metastasis after receiving
a HLA-A2 restricted survivin peptide plus adjuvant
[116]. Recently a phase I-II trial of vaccination with
HLA-A*0201-restricted peptides from prostate specific
membrane antigen (PSMA) and survivin was carried out
in 20 prostate cancer patients with biochemical failure
after surgery or radiotherapy. The vaccine consisted of
two peptides from PSMA (PSMA4-12 and PSMA711-
719) and one from survivin (SVV96-104/97M) given by
4 biweekly (priming) and then 4 monthly administra-
tions (boosting). To selectively eliminate regulatory
T cells (Tregs) and possibly enhance immunization, the
vaccinations were preceded by cyclophosphamide 300
mg/kq, i.v. The vaccine was well tolerated, with 14/20
patients exhibiting a significant although transient PSA
decrease. Most patients (19/20) showed a significant
increase of SVV96-104/97M-specific T cells, while a
response to PSMA was achieved in about half of the
patients. Increments of HLA-A*0201/SVV96-104/97M
or PSMA711-719 multimer+ CD8+ T cells were induced
in 50% and 35% of patients, respectively. However, vac-
cination-induced Ag-specific T cells displayed limited
cross-reactivity with HLA-A*0201+ prostate cancer cells.
These results indicate that the vaccine-induced Ag-spe-
cific CD8+ T cells had a reduced ability to cross-recog-
nize prostate cancer cells which could explain why PSA
control was achieved only transiently [117].
The tolerability, immunogenicity, and clinical efficacy
of three survivin peptides restricted to HLA A1, A2 and
B35 were addressed in a phase I/II trial which included
79 patients with metastatic melanoma (n = 61), pancrea-
t i c( n=8 ) ,c e r v i c a l( n=5 ) ,c o l o r e c t a l( n=2 ) ,a d r e n a l
gland (n = 2), and Merkel cell carcinoma (n = 1) who
failed to respond to systemic standard therapy. Peptide
vaccination was safe and vaccine-specific immune
responses were induced in 50% of the patients. Objec-
tive responses and control of disease were essentially
restricted to immunological responders. Three complete
responses and three partial responses were observed
(OR = 7.6%) with the duration of response ranging from
3 to 36+ months [118]. Due to these encouraging
results, ongoing Phase II studies are investigating survi-
vin based immunotherapy in patients with advanced
pancreatic, colon and cervical carcinomas as well as in
melanoma.
Survivin as a radiosensitizer
Survivin is known to play an important role in the sensi-
tivity of cells to radiation with high survivin levels corre-
sponding to reduced radiation sensitivity [119,120]. In a
number of preclinical studies inhibition of survivin
expression has been shown to sensitize tumor cells to
ionizing radiation [121-124]. Although apoptosis does
not play a major role in the response of solid tumors to
radiation as a single agent, inhibition of survivin prior to
irradiation leads to an increase in apoptosis and reduced
tumor cell survival [121]. In addition, survivin inhibition
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repair [125,126]. Consistent with these observations, a
number of small molecule inhibitors of survivin have
been shown to enhance the cytotoxic effects of radiation
[127]. Collectively, these findings provide a strong ratio-
nale for the clinical evaluation of survivin inhibitors
administered either concurrently or sequentially with
therapeutic radiation.
Conclusion
Over the last decade it has become increasingly clear that
inhibitor of apoptosis proteins play an integral role in
maintaining cellular homeostasis. In particular, one of
these proteins, survivin serves many functions involved
in cell survival including complex intracellular signaling,
stabilizing mitosis and facilitating cellular adaptation.
Much remains to be learned regarding the biology of sur-
vivin and other IAPs in terms of how these molecules
intersect with other pathways. Survivin is a highly
expressed in many different tumors and its expression
correlates with advanced disease, poorer survival, and
chemotherapy and radiation resistance. Because of the
role it plays, survivin is of increasing interest as a poten-
tial therapeutic target in cancer. Survivin antagonists may
function not as single protein inhibitors, but rather as
global pathway inhibitors that may disable multiple sig-
naling circuits in tumors. Clinical trials have highlighted
the problems with attempts to correlate survivin expres-
sion with clinical outcome. Small sample numbers, non-
uniform treatments, the presence of multiple alternatively
spliced survivin mRNAs with differing effects on apopto-
sis and the different methods of detection of survivin, all
lead to difficulty in trial interpretation. Further efforts are
required to achieve a greater understanding of the biol-
ogy of survivin and the other IAPs and more effectively
exploit strategies that target this protein in cancer.
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